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Aims. This study aims to investigate the possible synergistic interactions of the Danshen-Sanqi combination on vascular disease via
their anti-inflammatory activities.Methods. Nine combination ratios ofDanshen-Sanqi extracts were screened in theRAW264.7 cell
line and their anti-inflammatory effects were examined in lipopolysaccharide- (LPS-) induced nitric oxide (NO), tumor necrosis
factor (TNF), andmonocyte chemoattractant protein-1 (MCP-1) generation pathways.The interaction between Danshen and Sanqi
on each targetwas analysed using combination index (CI) and isobologrammodels. Additionally, the anti-inflammatory activities of
key bioactive compounds fromDanshen and Sanqi were tested using the samemodels.The compounds from each herb that exerted
the most potent activity were combined to evaluate their possible synergistic/antagonistic interactions. Results. Danshen-Sanqi 8 : 2
was found to be the optimal ratio and exerted a synergistic effect in inhibiting NO, TNF, and MCP-1 when the concentrations
were higher than 1.24, 1.89, and 2.17mg/mL, respectively. Although dihydrotanshinone I (DT) and ginsenoside Rd (Rd) from
Danshen and Sanqi, respectively, exhibited the greatest individual bioactivity in the assays, antagonistic effects were observed for the
DT-Rd combination 7 : 3. Conclusion. This study provided scientific evidence to support the traditional use of the Danshen-Sanqi
combination for vascular disease through their synergistic interactions on anti-inflammatory pathways.
1. Introduction
Vascular disease is a subgroup of cardiovascular diseases,
contributing to the leading cause of illness, disability, and
death worldwide. It describes an abnormal condition of the
blood vessels (arteries and veins) in the tissues or organs
mainly induced by vascular dysfunction [1]. Hypertension,
obesity, diabetes, high cholesterol levels, stress, and elevated
plasma homocysteine are all risk factors which could acceler-
ate the formation of vascular pathological changes [2]. The
development of vascular disease is complex and involves
interplay of various factors and signaling pathways and the
endothelial dysfunction is considered to be an earlymarker of
the disease [3]. Mounting evidence has suggested that proin-
flammatory responses induced by cytokines and chemokines
play a pivotal role in endothelial impairment, leading to
endothelial dysfunction, vascular inflammation, and the de-
velopment of many inflammatory vascular diseases [4–6].
As a major mediator of endothelium-dependent relax-
ation, nitric oxide (NO) is primarily generated by endothelial
nitric oxide synthase (eNOS) under normal conditions and
is essential in maintaining the healthy vascular homeostasis
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between vasodilation and vasoconstriction [7]. Under patho-
logical conditions, however, NO is produced by inducible
nitric oxide synthase (iNOS) in response to inflammatory
mediators such as lipopolysaccharide (LPS). Its increased
expression has been associated with nitrosative stress and
impaired vascular function in inflammatory vascular diseases
[8]. Tumor necrosis factor (TNF), a major inflammatory
mediator, has direct impact on the downregulation of eNOS
expression, which impairs endothelium-dependent, NO-
mediated vasodilation [9–11]. It is also linked with other
risk factors for vascular disease including lipid metabolism,
normal aging, and high-fat and high-carbohydrate diets [7].
For atherosclerotic vascular disease, it has been reported that
monocyte chemoattractant protein-1 (MCP-1) contributes to
the triggering of atherosclerotic plaque growth and rupture.
Its increased expression leads to the upregulation of adhesion
molecules, which aggravates the formation of atherosclerotic
lesions and thrombin [12]. Therefore, the suppression of
proinflammatory agents such as iNOS-induced NO, TNF,
and MCP-1 represents a potential biological target for the
management of inflammatory vascular diseases [13].
It is well recognised that combinational drug therapy is an
ideal treatment for vascular diseases due to its complex aetiol-
ogy and pathophysiology. As combinational drug therapy has
become a core treatment strategy for other complex diseases
such as cancer, diabetes, and HIV infection, significant
progress has been made in the development of mathematical
and computational models to facilitate the determination of
the synergism of the drugs. Combination index (CI) and
isobolograms are well-accepted and practical methods for
the analyses of the synergistic/antagonistic interactions of
combinational agents acting on the same target/receptor [14].
Traditional Chinese medicine (TCM) employs multiherbal
formulations for the prevention and treatment of various dis-
eases, with a concept that the multiple bioactive components
in the herbal formula can exert synergistic actions leading
to enhanced therapeutic effects. Salvia Miltiorrhiza Radix et
Rhizoma (Bunge, Lamiaceae, known as “Danshen” in TCM)
and Notoginseng Radix et Rhizoma (Burkill, F. H. Chen,
Araliaceae, known as “Sanqi” in TCM) are two of the most
popular and well-studied Chinese herbs. In particular, the
paired herb combination has been clinically used for years
and is officially listed in the Chinese Pharmacopoeia (as
Compound Danshen Tablet) with an indication for coronary
heart disease [15].
As single herbs, the effects of Danshen and Sanqi have
been well studied. For example, a clinical study in patients
with hypercholesterolaemia revealed that a Danshen extract
produced protective effects in endothelial progenitor cells
(EPCs) at least partially via reducing the expression of IL-
6 and TNF, highlighting its anti-inflammatory activity [16].
Results from previous studies in LPS-stimulated macrophage
cells have shown that lipid-soluble compounds of Danshen
including tanshinone I (T1), cryptotanshinone I (CT), dihy-
drotanshinone I (DT), and tanshinone IIA (TIIA) reduce
iNOS-induced NO, TNF, IL-1𝛽, PGE
2
, and MCP-1 levels [17–
19]. Panax notoginseng saponins (PNS) have been shown to
exert antiatherogenic effect through their anti-inflammatory
activity in an apolipoprotein E- (apoE-) deficient mouse
model and to produce dose-dependent inhibition of MCP-
1 mRNA expressions in a high-fat and chronically inflamed
induced atherosclerotic rabbit model [20, 21]. Additionally,
PNS attenuated atherosclerosis progression partially by sup-
pressing the release of MCP-1 in LPS-stimulated macrophage
cells [20]. Ginsenoside Rg1 (Rg1) and ginsenoside Re (Re),
two other key bioactive components of Sanqi, have also been
shown to reduce LPS-stimulated cytokines such as TNF in
vitromodels [22–24].
To date, however, little is known about the interactions
between the two herbs and the evidence for the combined
usage has not been elucidated. Therefore, this study aims to
investigate the combinational effects of Danshen-Sanqi pair
on proinflammatory mediators including TNF, NO (induced
by iNOS), and MCP-1 to elucidate their endothelial protec-
tion properties in RAW264.7 macrophages cell model. Pos-
sible synergistic interactions between the key bioactive com-
ponents from each herb were analysed using CI and isobolo-
gram models.
2. Materials and Methods
2.1. Preparation of Herbal Samples and Their Chemical Com-
pounds. Crude Danshen and Sanqi herbal materials were
sourced fromPuraPharm International Ltd., HongKong.The
raw herbal materials were authenticated by Professor Si-bao
Chen from theDepartment of Applied Biology and Chemical
Technology, the Hong Kong Polytechnic University, Hong
Kong, China, according to the Hong Kong Materia Medica
Standards. The aqueous extracts of Danshen (DS) and Sanqi
(SQ) were prepared as follows: 1 g of ground Danshen/Sanqi
crude herbal powder (30-mesh size) was weighed and soaked
with 30mL water for 0.5 hours, followed by refluxing with
boiling water for another 1 hour. The solution was then
centrifuged at 3000 rpm for 5min and the supernatant was
separated and evaporated to dryness using a freeze dryer. For
the preparation of the combined aqueous extracts of Danshen
and Sanqi (DS-SQ combination), the crude herbal powder
of Danshen and Sanqi was combined in nine different (w/w)
ratios (1 : 9, 2 : 8, 3 : 7, . . . , 8 : 2, 9 : 1), and proceeded to the
identical extraction procedure as single extract.
Chemical standards for Danshen including sodium dan-
shensu (DSS), salvianolic acid B (SB), salvianolic acid A
(SA), tanshinone TIIA (TIIA), dihydrotanshinone I (DT),
tanshinone I (TI), and cryptotanshinone (CT) and those for
Sanqi including ginsenoside Rg1 (Rg1), ginsenoside Rg2
(Rg2), ginsenoside Rd (Rd), ginsenoside Rb1 (Rb1), and noto-
ginsenoside R1 (NR1) were purchased from Chengdu Biop-
urify Phytochemicals Ltd. (Chengdu, China; purity >98%).
The standards were verified via liquid chromatography-mass
spectrometry.The standard stock solutions of these reference
compounds were prepared in methanol and stored at 4∘C
until further use.
2.2. Cell Culture. The murine RAW264.7 macrophages cells
were cultured at 37∘C in DMEM (Life Technologies, Victo-
ria, Australia) supplemented with 5% foetal bovine serum
(FBS) (Life Technologies, Victoria, Australia), 1% GlutaMax,
and 1% penicillin-streptomycin (Life Technologies, Victoria,
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Australia) in a humidified atmosphere containing 5% CO
2
and 95% air.
2.3. NO Assay. The NO production stimulated by LPS in
RAW264.7 cells was measured by its stable metabolite nitrite
based on the Griess reaction [25]. Briefly, cells (density at 1
× 106/mL) were seeded on 96-well cell culture plate (Corn-
ing Costar, Sigma, Australia) and incubated for 48 hours
followed by pretreatments with individual DS or SQ extracts
or DS-SQ combinations. After the cells were incubated
for 2 hours, 50 ng/mL of LPS was added to the cells and
coincubated for another 24 hours. LPS from Escherichia
coli 0111:B4 purified by trichloroacetic acid extraction (LPS,
Sigma, batch number 070M4018) was used to stimulate
inflammatory mediators including NO, TNF, and MCP-1.
After the LPS stimulation, 80 𝜇L of cells supernatant was
collected and mixed with Griess reagent (1% sulfanilamide in
5% phosphoric acid and 0.1% N-1-naphthylethylenediamine
dihydrochloride in Milli-Q water) for NOmeasurement.The
other part of the cell supernatant was used for TNF andMCP-
1 ELISA assay. The plate with mixed supernatant and Griess
reagent was monitored under 540 nm.
2.4. TNF and MCP-1 ELISA Assays. The stored supernatants
were analysed for TNF andMCP-1 synthesis using a commer-
cial ELISA kit (Peprotech, Queensland, Australia) according
to the manufacturer’s instructions. The absorbance was mea-
sured at 410 nm. The concentrations of TNF and MCP-1 in
the experimental samples were extrapolated from a standard
curve.
2.5. (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) (MTT) Assay. The cytotoxicities of the DS, SQ,
and DS-SQ extracts were tested using MTT assay. MTT
(0.5mg/mL) was added to the cells and incubated for 4
hours. The supernatant was then discarded and replaced
with the same amount of dimethyl sulfoxide (DMSO) (Sigma,
Australia) and the optical density was measured using a
microplate reader (BMG LABTECH FLUOstar OPTIMA,
Mount Eliza, Victoria, Australia) at 510 nm. The density of
formazan formed in control (medium with vehicle) cells was
taken as 100% of cell viability.
2.6. Determination of Synergistic, Additive, or Antagonistic
Interactions. Potential interactions of the combined extract
were determined using the CImodel based on Chou-Talalay’s
method [26]. Firstly, the concentration-response curves of
the individual extract/compounds and their combinations
in a fixed ratio pertaining to the bioassay were constructed
and entered into CalcuSyn software 2.0 (Biosoft, USA). The
combination index-fraction affected (CI-Fa) curve, isobolo-
gram figure, and the relevant statistics regarding the syn-
ergistic/antagonistic interactions were generated. The CI-Fa
curve demonstrated the relationship between the CI value
and the effective level on a certain biological target (i.e., the
suppressive effect on NO). The CI values denoted synergism
(CI < 1), additive effect (CI = 1), and antagonism (CI > 1).
This curve exhibited the synergistic/antagonistic interaction
at a particular effective range.
Table 1: IC
50
values of DS, SQ, and DS-SQ in inhibiting NO, TNF,
and MCP-1 expressions induced by LPS on RAW264.7 cells.
Danshen : Sanqi IC50 (mg/mL)
NO TNF MCP-1
0 : 10 2.06 1.71 1.87
1 : 9 1.10 0.72 0.86
2 : 8 1.39 1.29 1.94
3 : 7 1.27 0.84 1.68
4 : 6 1.26 1.07 1.72
5 : 5 1.59 1.22 1.34
6 : 4 1.11 0.80 0.99
7 : 3 1.40 0.61 0.69
8 : 2 0.34 0.85 0.97
9 : 1 2.98 1.02 1.49
10 : 0 2.19 1.43 1.39
2.7. Statistical Analysis. All data were expressed as mean ±
SEM (𝑛 ≥ 3). The statistical differences were analysed using
one-way ANOVA followed by Tukey’s Honestly Significant
Difference (HSD) test. Values of 𝑝 < 0.05 were considered
statistically significant.
3. Results
3.1. Effects of DS, SQ, and DS-SQ on the Inhibition of Inflam-
matory Mediators Stimulated by LPS in RAW264.7 Cells
3.1.1. Inhibitory Effects of DS, SQ, and DS-SQ on Nitrite
Release. In the presence of LPS (50 ng/mL), a significant
amount of nitrite production was detected and reached
215.56 ± 8.38 and 197.40 ± 3.36 𝜇g/mL in sterile water
and DMSO vehicle solutions, respectively. A highly selective
iNOS inhibitor dihydrochloride (1400W) was used as the
positive control in thismodel and showed a strong nitrite sup-
pressive effect, with a half-maximal inhibitory concentration
(IC
50
) value at 5.53 𝜇M.
All tested single and combinational extracts of Danshen
and Sanqi showed NO inhibitory effects in a dose-dependent
manner (Figure 1) without the impairment of cell viability. At
2.5mg/mL, DS and SQ significantly inhibited LPS-induced
NO production in RAW264.7 cells by 56.08 ± 1.00% and
59.58 ± 2.42%, respectively. The IC
50
values for DS and SQ
in inhibiting NO were 2.19 and 2.06mg/mL, respectively
(Table 1). All DS-SQ combinations showed NO inhibitory
effects in a dose-dependent manner, with IC
50
values ranging
from 0.34 to 2.98mg/mL. It is noteworthy that the IC
50
values
for all DS-SQ combinations were lower than those of the
single extracts except DS-SQ 9 : 1. DS-SQ 8 : 2 demonstrated
the strongest NO inhibitory effect with the lowest IC
50
value
of 0.34mg/mL, and at 2.5mg/mL the NO generation was
reduced by 77.29 ± 1.85% (𝑝 < 0.001).
3.1.2. Inhibitory Effects of DS, SQ, and DS-SQ on TNF Release.
In the presence of LPS (50 ng/mL), a significant amount
of TNF production was detected and reached 870.08 ±
44.22 pg/mL in DMSO vehicle solution. The LPS-induced
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Figure 1: The suppressive effects of DS, SQ, and DS-SQ 8 : 2 on LPS-induced NO production are shown in (a), (b), and (c), respectively.
(d) Isobologram curves of DS, SQ, and DS-SQ. (e) Combination index (CI) values were plotted as a function of fractional suppression of
NO production (Fa) by “CalcuSyn” software. Dotted line is the reference line, where CI value is equal to 1; solid line represents CI values
at different Fa. Fa values correspond to % suppression. ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001 as compared to LPS stimulation only by
one-way ANOVA.
TNF production in RAW264.7 cells was suppressed by DS
(0.01–2.5mg/mL), SQ (1.25–2.5mg/mL), and DS-SQ (0.1–
5.0mg/mL) extracts in a dose-dependent manner (Figure 2)
with no cytotoxicity. DS and SQ inhibited TNF production
by 66.38 ± 9.92% (𝑝 < 0.001) and 70.93 ± 0.33% (𝑝 <
0.001), respectively, at 2.5mg/mL, with IC
50
values of 1.43
and 1.71mg/mL, respectively (Table 1). Similarly, all DS-SQ
combinations showed TNF inhibitory effects in a dose-
dependent manner, with IC
50
values ranging from 0.61 to
1.29mg/mL. These values were lower than of the DS and
SQ individual extracts, suggesting stronger inhibitory effects
by the combination. The inhibitory effects generated by DS-
SQ 6 : 4 to 8 : 2 appeared to be relatively stronger than other
combinations (IC
50
from 0.61 to 0.85mg/mL), with DS-SQ
7 : 3 (0.1−5mg/mL) having the most potent effect with the
lowest IC
50
value (0.61mg/mL). DS-SQ 8 : 2 (0.1−5mg/mL),
which produced the greatest NO inhibitory effect, also
showed amarked effect on TNF (66.57±2.93% at 2.5mg/mL;
IC
50
= 0.85mg/mL).
3.1.3. Inhibitory Effects of DS, SQ, and DS-SQ on MCP-1
Release. In the presence of LPS (50 ng/mL), a significant
amount of MCP-1 production was detected and reached
2435.38±156.45 pg/mL inDMSOvehicle solution. Individual
DS (0.01−2.5mg/mL) and SQ (0.01−2.5mg/mL) extracts sup-
pressed LPS-inducedMCP-1 generation in a dose-dependent
manner, with IC
50
value at 1.39 and 1.87mg/mL, respectively
(Figure 3, Table 1). At a concentration of 2.5mg/mL, DS and
SQ inhibited MCP-1 production by 87.53 ± 1.14% (𝑝 < 0.01)
and 71.37 ± 3.42% (𝑝 < 0.01), respectively. All DS-SQ
combinations (except DS-SQ 2 : 8) demonstrated a greater
MCP-1 suppressive effect than DS and SQ alone, with IC
50
values ranging from 0.69 to 1.94mg/mL. Relatively stronger
effects were found in theDS-SQ combinations that havemore
DS (6 : 4 to 9 : 1), withDS-SQ7 : 3 demonstrating the strongest
effect (IC
50
0.69mg/mL). DS-SQ 8 : 2 (0.1−5mg/mL) also
exerted a potent effect in the MCP-1 assay and produced an
89.75 ± 4.73%MCP-1 reduction at 2.5mg/mL.
All inhibitory effects of DS, SQ and DS-SQ combinations
on the above assays were not due to cytotoxicity.
3.1.4. Optimised Ratio of DS-SQ Combinations in NO, TNF
and MCP-1 Assays. Based on the above results from the NO,
TNF, and MCP-1 assays (as shown in Table 2), DS-SQ 8 : 2
consistently produced low IC
50
values in the suppression of
the three inflammatory mediators (NO, TNF, and MCP 1)
and, therefore, was selected as the optimal ratio for anti-
inflammatory activity.
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Figure 2: Dose-response curves of TNF production (%) versus concentration (mg/mL) for DS, SQ, andDS-SQ 8 : 2 on ELISA assays as shown
in (a), (b), and (c). (d) Isobologram curves for DS, SQ, and DS-SQ 8 : 2 on TNF ELISA assay. (e) CI values versus DS-SQ 8 : 2 TNF inhibition
effect (Fa). Solid line represents CI values at different Fa. Fa values correspond to % suppression. ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001 as
compared to LPS stimulation only by one-way ANOVA.
Table 2: Inhibitory effects of DS, SQ, and DS-SQ 8 : 2 on LPS-
induced NO, TNF, and MCP-1 production in RAW264.7 cells at
2.5mg/mL.
Tested extracts
Inhibition of LPS-induced proinflammatory
mediators (% ± SEM)
NO TNF MCP-1
DS 56.08 ± 1.00 66.38 ± 9.92 87.53 ± 1.14
SQ 59.58 ± 2.42 70.93 ± 0.33 71.37 ± 3.42
DS-SQ 8 : 2 77.29 ± 1.85 66.57 ± 2.93 89.75 ± 4.73
3.1.5. Synergy Determination of DS-SQ 8 : 2 in Inhibiting
NO, TNF, and MCP-1. Based on the dose-response curves
of the DS, SQ, and DS-SQ 8 : 2 (Figures 1, 2, and 3), CI
values at specific effect level (e.g., half-maximal effective
dose, ED
50
) were calculated using “CalcuSyn” software with
classical isobologram equation. Isobologram curves (Figures
1(d), 2(d), and 3(d)) and CI-Fa curves (Figures 1(e), 2(e), and
3(e)) were generated, so that CI values at different effect levels
could be easily compared.
As shown in Figure 1(d), DS-SQ 8 : 2 isobologram pro-
duced a synergistic effect in inhibiting NO generation in-
dicating that lower concentrations were required of the
combination to reach the same effect level compared with
that of the single extracts at ED
50
, ED
75
, and ED
90
. Moreover,
this synergistic effect was confirmed by the CI-Fa curve of
DS-SQ 8 : 2, with Fa value > 0.4 (40% of the NO inhibition).
Thus, it was calculated that DS-SQ 8 : 2 exerted synergistic
effects when its concentration was higher than 1.24mg/mL
(Figure 1(e)).
Similarly, as shown in Figure 2(d), the isobologram
showed a synergistic interaction between DS-SQ 8 : 2 in
inhibiting TNF at 90% inhibitory effect level (ED
90
). The CI-
Fa curve in Figure 2(e) suggested that there was a synergistic
effect when Fa value was greater than 0.523 for DS-SQ 8 : 2.
The corresponding synergistic concentration for DS-SQ 8 : 2
was calculated to be above 1.89mg/mL.
In Figure 3(d), the isobologram showed synergistic inter-
actions for DS-SQ 8 : 2 in inhibiting MCP-1 at 75 and 90%
inhibitory effect levels (ED
75
andED
90
). Furthermore, theCI-
Fa curve revealed a biphasic effect: a synergistic effect was
produced when the DS-SQ 8 : 2 concentrations were greater
than 2.17mg/mL and vice versa, indicating an antagonistic
effect (Fa < 0.7) (Figure 3(e)).
In summary, the minimum concentrations of DS-SQ 8 : 2
to exert synergistic effects in inhibiting LPS-induced NO,
TNF, and MCP-1 release were 1.24, 1.89, and 2.17mg/mL,
respectively (Table 3).
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Figure 3: Dose-response curves of MCP-1 production (%) versus concentration (mg/mL) for DS, SQ, and DS-SQ 8 : 2 on ELISA assays as
shown in (a), (b), and (c). (d) Isobologram curves for DS, SQ, and DS-SQ 8 : 2 onMCP-1 ELISA assay. (e) CI values versus DS-SQ 8 : 2 MCP-1
inhibition effect (Fa). Solid line represents CI values at different Fa. Fa values correspond to % suppression. ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and
∗∗∗𝑝 < 0.001 as compared to LPS stimulation only by one-way ANOVA.
Table 3: Dose range of DS-SQ 8 : 2 and DT-Rd 7 : 3 which showed synergistic effect (CI < 1) calculated by CalcuSyn.
Synergy dose range
Combination NO assay TNF ELISA assay MCP-1 ELISA assay
DS-SQ 8 : 2 >1.24mg/mL >1.89mg/mL >2.17mg/mL
DT-Rd 7 : 3 >22.85 𝜇g/mL >2.22𝜇g/mL <0.053 𝜇g/mL
Data was obtained from CalcuSyn.
3.2. Inhibitory Effects of Bioactive Components of Danshen and
Sanqi on Inflammatory Mediators
3.2.1. Effects on NO Production. Most of the bioactive com-
pounds tested demonstrated dose-dependent inhibition of
NO production. SB (1–1000 𝜇M) and Rg1 (1–800 𝜇M), the
two most abundant compounds of DS and SQ, respectively,
produced amaximum reduction of NO generation by 72.16±
5.8% and 18.67 ± 3.77%, respectively, with an IC
50
value of
108.30 𝜇M for SB (Table 4). By contrast, the relatively lipid-
soluble compounds (DT, CT, T1, Rg2, and Rd) showed greater
NO inhibition (IC
50
ranging from4.64 to 116.80) compared to
their water-soluble counterparts (NR1, Rg1, Rb1, DSS, SA, and
SB) as evidenced by significantly lower IC
50
values (ranging
from 26.02 to 144.10 𝜇M) (𝑝 < 0.5) (Table 4). DT (3.91–
15.63 𝜇M) and Rd (10–100 𝜇M) were found to be the key
compounds responsible for NO inhibition (95.16±0.25% and
88.00 ± 2.14% at the maximum, with IC
50
values at 4.64 and
7.89 𝜇M, resp.) and were comparable to those of the positive
control dihydrochloride (IC
50
= 5.53 𝜇M).
3.2.2. Effects on TNF Production. Similar to the results in the
NO assay, the relatively lipid-soluble compounds (CT, DT, TI,
Rb2, Rg2, and Rd) caused dose-dependent inhibition of LPS-
induced TNF production, with the IC
50
ranging from 1.98 to
28.64 𝜇M without cytotoxicity (Table 4). With the exception
of Rb1, the inhibitory effects of the relatively water-soluble
compounds did not reach 50% even after the concentration
was raised to 1000𝜇M. CT (10–31.25 𝜇M) and Rd (0.1–
200𝜇M) were found to be the most potent compounds in
inhibiting TNF production (93.28±9.24% and 86.84±1.61%
at the maximum), with IC
50
values at 1.98 and 9.79𝜇M,
respectively. DT (20–31.25𝜇M) exerted a potent inhibitory
effect (85.70 ± 2.49% at the maximum).
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Table 4: IC
50
values of the key bioactive compounds of Danshen and Sanqi in NO, TNF, and MCP-1 assay.
DS compounds IC50 (𝜇M)
NO TNF-𝛼 MCP-1
Relatively water-soluble components
DSS 144.10 NA NA
SA 90.23 NA NA
SB 108.30 NA NA
Relatively lipid-soluble components
CT 116.80 1.98 11.32
DT 4.64 24.25 13.97
T1 5.45 7.627 NA
TIIA NA NA NA
SQ compounds IC50 (𝜇M)
NO TNF-𝛼 MCP-1
Relatively water-soluble components
NR1 92.05 NA NA
Rg1 NA NA NA
Re 26.02 NA NA
Rb1 53.9 71.36 NA
Relatively lipid-soluble components
Rb2 134.90 28.44 NA
Rg2 66.41 28.64 NA
Rd 7.89 9.79 36.00
NA: the maximum inhibitory effect less than 50%.
3.2.3. Effects on MCP-1 Production. In the MCP-1 assay,
only CT, DT, and Rd caused inhibitory effects on MCP-1
generation, with IC
50
values of 11.32, 13.97, and 36.00 𝜇M,
respectively. No cytotoxicity was observed. Other tested
compounds did not show any significant MCP-1 inhibitory
effect (𝑝 > 0.05). Among the three bioactive compounds, DT
(20𝜇M) and Rd (100 𝜇M) produced potent inhibitory effects
(82.26 ± 7.91% and 56.57 ± 5.98%, resp.).
The concentrations for all the tested bioactive compounds
in the NO, TNF, and MCP-1 bioassays were within their safe
dosage for RAW264.7 cells.
3.2.4. Interactions between DT and Rd in Inhibiting NO, TNF,
and MCP-1 Release. DT from Danshen and Rd from Sanqi
were found to be the most potent bioactive compounds in
inhibiting LPS-induced NO, TNF, and MCP-1 generation
(Figures 4–6, Table 4) and thus were evaluated for their
potential synergic interactions.
The IC
50
values for the DT-Rd combinations in various
ratios (1 : 9, 2 : 8, . . . , 8 : 2, 9 : 1 (w : w)) ranged from 2.08
to 36.65 𝜇g/mL (Table 5). DT-Rd combinations with the ratio
of 1 : 9 to 5 : 5 showed significantly higher IC
50
values (12.47–
36.65 𝜇g/mL) in inhibiting NO than other combinations
(IC
50
values 1.28–7.36𝜇g/mL) (𝑝 < 0.05). The NO inhibitory
effects of the DT-Rd combinations became stronger when the
DT proportion increased, with DT-Rd ratios from 7 : 3 to 9 : 1
showing comparable IC
50
values as that of DT on its own.
A similar trend was found for TNF inhibition; the combi-
nationswith a higher proportion ofDT (7 : 3 to 9 : 1) produced
greater inhibitory effects (IC
50
values ranging from 2.01 to
9.10 𝜇g/mL) than those with a lower DT ratio (IC
50
values
ranging from 9.41 to 35.56 𝜇g/mL). Among them, the DT-Rd
7 : 3 combination showed the greatest inhibitory effect, with
an IC
50
value of 2.01𝜇g/mL, which was significantly lower
than that of DT and Rd on their own.
Table 5: IC
50
value of DT-Rd combination in NO, TNF, and MCP-1
ELISA assays.
DT-Rd ratio IC50 value (𝜇g/mL)
NO TNF-𝛼 MCP-1
0 : 10 7.47 12.06 34.10
1 : 9 33.72 31.20 48.50
2 : 8 36.65 35.56 56.35
3 : 7 26.66 33.46 92.15
4 : 6 25.46 25.67 29.03
5 : 5 12.47 9.41 34.47
6 : 4 7.36 31.03 47.13
7 : 3 2.08 2.01 12.21
8 : 2 2.53 2.46 16.06
9 : 1 1.28 9.10 14.52
10 : 0 1.29 87.14 3.89
In the MCP-1 assay, all DT-Rd combinations showed
significantly higher IC
50
values (12.21–92.15 𝜇g/mL) than that
of DT (IC
50
= 3.89 𝜇g/mL) on its own. In spite of this, DT-Rd
(7 : 3) exhibited significantly lower IC
50
(12.21𝜇g/mL) than
Rd on its own (IC
50
= 34.10 𝜇g/mL), suggesting the greatest
inhibitory effect among all DT-Rd combinations.
3.2.5. Synergy Determination of DT-Rd Combination. The
DT-Rd 7 : 3 combination consistently showed greater inhibi-
tory effects on NO, TNF, andMCP-1 production in the assays
(IC
50
values were 2.08, 2.01, and 12.21𝜇g/mL, resp.) when
compared with other combinations and was therefore con-
sidered to be the optimised ratio for synergistic interactions.
Both the isobologram and the CI-Fa curve suggested
that the DT-Rd 7 : 3 combination exhibited an antagonistic
inhibitory effect on LPS-induced NO generation (CI value
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Figure 4: Dose-effect curves for DT, Rd, and DT-Rd (7 : 3) on NO assay as shown in (a), (b), and (c). (d) Isobologram curves for DT, Rd, and
DT-Rd (7 : 3) on NO. (e) CI values versus NO inhibition effect (Fa) by “CalcuSyn” software. Dotted line is the reference line, where CI value
is equal to 1; solid line represents CI values at different Fa. Fa values correspond to % suppression. ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001
as compared to LPS stimulation only by one-way ANOVA.
was at 1.79 at Fa = 0.5) (Figures 4(d) and 4(e)). Similar
antagonistic effect was observed in the TNF assay when the
concentration of DT-Rd (7 : 3) was lower than 103.92 𝜇g/mL
(Fa > 0.744) (Figures 5(d) and 5(e)). A slight synergistic effect
on MCP-1 generation was shown when Fa was lower than
0.584. The interaction tended to be additive when Fa was
increased to 0.6. Antagonism was observed and predicted to
be stronger when Fa was higher than 0.6 (the concentration
for DT-Rd was calculated to be higher than 12.65 𝜇g/mL).
4. Discussion
The anti-inflammatory effects of Danshen and Sanqi as single
herbs have been well demonstrated in previous in vitro and
in vivo studies and were confirmed in the current study.
In addition, our results demonstrated synergistic effects of
the Danshen-Sanqi combinations on the aforementioned
key anti-inflammatory events using the CI and isobologram
models. To the best of our knowledge, this is the first report
of the synergistic effects of a Danshen-Sanqi combination on
anti-inflammatory pathway associatedwith vascular diseases.
Our results showed that the aqueous extract of Danshen
significantly inhibited LPS-induced NO, TNF, and MCP-
1 production in RAW264.7 cells, which is consistent with
the previous in vitro and in vivo findings. The inhibitory
effects of Danshen have been suggested to be associated with
the attenuation of mRNA expressions of the inflammatory
mediators [27, 28]. Further, our study has demonstrated for
the first time that lipid-soluble components of Danshen (e.g.,
DT, T1, and CT) produced a greater inhibitory effect on NO
production than their water-soluble counterparts (e.g., DSS,
SA, and SB). Specifically, DTwas found to exert a comparable
inhibitory effect on NO to that of dihydrochloride, a specific
iNOS inhibitor, highlighting its anti-inflammatory potential
as a single chemical entity. The anti-inflammatory activities
of tanshinones reported in this study are compatible with the
findings of previous studies. It was demonstrated that lipid-
soluble extracts of Danshen were capable of inhibiting the
LPS-induced gene and protein expression of iNOS, TNF, IL-
1𝛽, and IL-6 in macrophages via blocking NF-𝜅B activation
[18, 19]. It was also previously reported that CT downregu-
lated the expression of proinflammatory enzymes, including
COX-2 and iNOS [18]. Many in vitro studies suggest that
TIIA is a key bioactive component of Danshen responsible
for its anti-inflammatory activities through suppressing LPS-
stimulated NO, IL-1𝛽, IL-6, and MCP-1 expressions [29–31].
In this study, the Sanqi extract also demonstrated signif-
icant inhibitory effects on NO, TNF, and MCP-1 production
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Figure 5: Dose-effect curves for DT, Rd, and DT-Rd (7 : 3) on TNF assay as shown in (a), (b), and (c). (d) Isobologram curves for DT, Rd, and
DT-Rd (7 : 3) on TNF. (e) CI values versus TNF inhibition effect (Fa) by “CalcuSyn” software. Solid line represents CI values at different Fa.
Fa values correspond to % suppression. ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001 as compared to LPS stimulation only by one-way ANOVA.
which has been suggested to be associated with downregu-
lating the expression of COX-2 mRNA and blockage of NF-
𝜅B via LXR𝛼 [32]. Ginsenosides from Sanqi were found to
be the key components contributing to its anti-inflammatory
effects via multiple mechanisms [33]. Rb1 and Rb2 have been
suggested to block TNF production and to attenuate NO and
PGE2 via repression of NF-𝜅B activation signals. Rg1 and
Re have been shown to inhibit NO and TNF production via
ERK and JNK pathways, and Rb2 was shown to target cAMP
PDE [33]. It was demonstrated that the anti-inflammatory
mechanism of Rd was associated with inhibiting iNOS and
COX-2 expression [33]. Our results support these findings
and found Rd as the key ginsenoside compound (lowest IC
50
value) responsible for the anti-inflammatory properties of
Sanqi [33].
Danshen and Sanqi have been widely used in combi-
nation clinically for the treatment of various cardiovascular
diseases. This combinational approach is common in TCM
practice based at least partially on an assumption that
various components of herbs in complex herbal formulations
can interact to produce synergistic effects leading to better
therapeutic outcomes. In TCM, the ratio (dosage) of herbal
ingredients is tailored to each patient in order to reach a
desirable clinical outcome based on syndrome-differentiation
treatment strategy. As recorded in a classic TCM text-
book, Danshen should be used at a higher proportion in
the DS-SQ combination in the early stages of cardiovascu-
lar disease when pathological changes of the organs have
not occurred, whereas the proportion of Sanqi should be
increased at the later stage of the disease [34]. However,
the scientific evidence to support this theory is limited. In
a previous study, a higher proportion of Danshen in the
combination (10 : 3–10 : 7) was also shown to be better than
Danshen or Sanqi alone for improving myocardial ischaemia
and inhibiting platelet adhesion and aggregation in vivo
[35]. It was assumed that this enhanced biological activity
of the combination was associated with its altered chemical
composition during the mixed preparation. Interestingly, an
analytical study by Zeng et al. supported this assumption,
which showed that the extraction yield of the chemical
constituents of Danshen was increased in the codecocted
Danshen and Sanqi mixtures, with the ratio of 5 : 3 yielding
the highest quantity of chemical constituents from Danshen
[36]. This suggests that the amount of the components in
Danshen was increased in the presence of Sanqi in the
mixture. This may be due to Sanqi providing an environ-
ment which solubilises the Danshen compounds due to the
hydrophilic/hydrophobic nature of the saponins. This is the
first study that systematically evaluated the synergy of Dan-
shen and Sanqi combinations on three anti-inflammatory
pathways. We found that the DS-SQ 8 : 2 combination pro-
duced the strongest anti-inflammatory effects. Moreover, the
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Figure 6: Dose-effect curves for DT, Rd, and DT-Rd (7 : 3) on MCP-1 assay as shown in (a), (b), and (c). (d) Isobologram curves for DT,
Rd, and DT-Rd (7 : 3) on MCP-1. (e) CI values versus MCP-1 inhibition effect (Fa) by “CalcuSyn” software. Solid line represents CI values
at different Fa. Fa values correspond to % suppression. ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001 as compared to LPS stimulation only by
one-way ANOVA.
combination reached synergistic effects (CI < 1) in inhibiting
LPS-induced NO, TNF, and MCP-1 when the concentration
was greater than 1.24mg/mL, 1.89mg/mL, and 2.17mg/mL,
respectively. The optimal ratio of Danshen-Sanqi at 8 : 2 for
the anti-inflammatory activity supports the traditional DS-
SQ combination for the early stage of cardiovascular disease
whereby a higher proportion of Danshen is used [34]. In
addition, these results have provided strong evidence to
support synergistic interactions in this 2-herb combination.
A previous study applied systems biology to explain the syn-
ergistic action of Danshen-Sanqi at themolecular level. It was
discovered that Danshen, when used in a higher proportion,
was the key player, and its chemical compounds bound to
themain targets involved in cardiovascular disease. However,
the presence of Sanqi provided an overall stronger outcome
by serving as an “assistant” whereby its chemical compounds
bound to other associated targets [37].Therefore, this reflects
the traditional theory of the combinationwherebyDanshen is
the primary herb at a higher dosage and Sanqi is the assistant
herb at a lower dosage.
In terms of a pharmaceutical combination, it is inter-
esting to note that although DT-Rd 7 : 3 produced the most
prominent inhibitory effects onNO, TNF, andMCP-1 release,
an antagonistic relationship between the two components
was identified. This suggests that combining two potent
compounds may not necessarily engage a stronger effect
and, in fact, may lead to a reduced response (antagonism)
compared with individual effects. One possibility is that
single, active compounds may compete for/saturate the same
cellular receptor/metabolic pathways, leading to lower than
expected cellular responses than predicted.
The anti-inflammatory effects of Danshen-Sanqi com-
binations have been demonstrated with in vitro models in
this study. However, we recognise that the cellular assays
used in this study serve as a preliminary screening method.
Whether the Danshen-Sanqi 8 : 2 combination can be applied
to a broader range of inflammatory mediators and other in
vitro/in vivo/clinical systems is yet to be determined. Addi-
tionally, in-depth investigation on Danshen-Sanqi 8 : 2 such
as signaling pathways, target protein, and gene expressions
may need to be examined in future studies.
5. Conclusions
Theresults showed that theDanshen-Sanqi combinationwith
a ratio of 8 : 2 synergistically enhanced their inhibitory activi-
ties on LPS-inducedNO, TNF, andMCP-1 in RAW264.7 cells.
Additionally, the relatively nonpolar compounds of the herbs
demonstrated stronger effects than their polar counterparts,
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suggesting a greater role of the lipid-soluble components in
the anti-inflammatory activities of the two herbal extracts.
DT andRd, two lipophilic compounds derived fromDanshen
and Sanqi, respectively, were found to be the most potent
compounds in inhibiting the LPS-induced NO, TNF, and
MCP-1 production.However, DT-Rd combinations produced
antagonistic interactions. In summary, this study provides
early evidence to support the traditional use of the Danshen-
Sanqi combination.
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